Shaji Kumar, MD, Mayo Clinic, Rochester, MN, outlines the updated results from the BELLINI trial (NCT02755597), a Phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).